446 Views | 613 Downloads
E-mail: dweinshenker@genetics.emory.edu
Conceived and designed the experiments: DW MG PMI.
Performed the experiments: MG LCL.
Analyzed the data: MG DW.
Contributed reagents/materials/analysis tools: DW PMI.
Wrote the paper: MG DW.
We thank Dainippon-Sumitomo Pharmaceuticals Inc. (Osaka, Japan) for providing the DOPS needed to maintain our Dbh mouse colony, Synosia Therapeutics for providing the nepicastat, and C. Strauss for helpful editing of the manuscript.
MGC, LCL, and PMI declare no conflict of interest.
DW is co-inventor on a patent concerning the use of selective DBH inhibitors for the treatment of cocaine dependence (US-2010-015748-A1; “Methods and Compositions for Treatment of Drug Addiction”).
This patent does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, has not been licensed, and DW has received no compensation under its auspices.
This work was supported by the National Institute of Drug Abuse (DA017963 and DA027535 to DW, DA25040 and DA015040 to MGC) and the National Eye Institute (EY004864 and P30 EY06360 to PMI).
© 2012 Gaval-Cruz et al.